WebCyclophosphamide is an oxazaphosphorine that contributes alkyl groups to DNA, forming covalent linkages. It depletes T and B cells and suppresses antibody production. It is metabolized to 4-hydroxycyclophosphamide and its tautomer aldophosphamide by liver cytochrome P450 enzyme. WebJul 27, 2024 · Attributed to chemical irritation by accumulation of cyclophosphamide active metabolites in concentrated urine. For prevention, instruct patients to increase fluid intake for 24 hours before, during, and for at least 24 hours following cyclophosphamide administration, and to void frequently for 24 hours after receiving the drug.
PharmGKB
WebSep 5, 2024 · Cyclophosphamide is one of the primary cytotoxic agents commonly used in conditioning chemotherapy regimens for hematopoietic cell transplant (HCT). 1 It is the final metabolite responsible for alkylation; it undergoes further nonenzymatic degradation to form nor-nitrogen mustard that alkylates position N-7 guanine that is responsible for cellular … WebCyclophosphamide and ifosfamide are alkylating agents administered to treat malignant disease. They are prodrugs and require activation by hepatic microsomal enzymes before being metabolized to their respective cytotoxic species, phosphoramide mustard and ifosfamide mustard. howard schultz to testify
Kinetics of Cyclophosphamide Metabolism in Humans, Dogs, Cats ... - PubMed
WebApr 14, 2024 · Twelve Asian patients with sarcoma received interval-compressed (ic-) chemotherapy scheduled every 14 days with a regimen of vincristine (2 mg/m2), doxorubicin (75 mg/m2), and cyclophosphamide (1200–2200 mg/m2) (VDC) alternating with a regimen of ifosfamide (9000 mg/m2) and etoposide (500 mg/m2) (IE), with filgrastim … WebJul 22, 2024 · Cyclophosphamide can cause myelosuppression (leukopenia, neutropenia, thrombocytopenia and anemia), bone marrow failure, and severe immunosuppression … WebCyclophosphamide is an alkylating agent with potent cytotoxic and immunosuppressive effects. A randomized, triple arm study demonstrated a positive effect in SPMS patients treated with a 2-week course of cyclophosphamide/ACTH as compared to patients who received ACTH alone (Hauser et al., 1983). howard schultz transformational leadership